FMP

FMP

Enter

SLNO - Soleno Therapeutics, Inc.

Profile of Soleno Therapeutics, Inc.(SLNO), Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development an

photo-url-https://financialmodelingprep.com/image-stock/SLNO.png

Soleno Therapeutics, Inc.

SLNO

NASDAQ

42.8 USD

-0.05 (-0.117%)

About

ceo

Dr. Anish Bhatnagar M.D.

sector

Healthcare

industry

Biotechnology

website

https://soleno.life

exchange

NASDAQ

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

CIK

0001484565

ISIN

US8342033094

CUSIP

834203200

Address

203 Redwood Shores Parkway

Phone

650 213 8444

Country

US

Employee

33

IPO Date

Nov 13, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep